4-氯-1(2H-)-异喹啉酮 | 56241-09-9

• 物质功能分类: 医药中间体 - 异喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 4-氯-1(2H-)-异喹啉酮
• 中文别名: 4-氯-1(2H)-异喹啉酮；4-氯异喹啉-1(2H)-酮；4-氯-2H-异喹啉-1-酮；1-羟基-4-氯异喹啉
• 英文名称: 4-chloro-1-(2H)-isoquinolone
• 英文别名: 4-Chlorisocarbostyril；4-chloro-2H-isoquinolin-1-one；4-Chloro-1(2H)-isoquinolone；4-chloro-2H-isoquinolin-1-one
• CAS: 56241-09-9
• 化学式: C₉H₆ClNO
• mdl: MFCD01861859
• 分子量: 179.606
• InChiKey: MVWIXKFNHOXLBU-UHFFFAOYSA-N

物化性质

• 熔点：
  235-237℃ (DEC)
• 沸点：
  394.2±42.0 °C(Predicted)
• 密度：
  1.38

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  1,4-二氯异喹啉	1,4-dichloro-1,2-dihydrocyclobutisoquinoline	15298-58-5	C9H5Cl2N	198.051

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  4-氯-1-氧代-1,2-二氢-7-异喹啉磺酰氯	4-chloro-1-oxo-1,2-dihydro-7-isoquinolinesulfonyl chloride	223671-81-6	C9H5Cl2NO3S	278.116
  ——	2-acetyl-4-chloro-2H-isoquinolin-1-one	110514-25-5	C11H8ClNO2	221.643
  1,4-二氯异喹啉	1,4-dichloro-1,2-dihydrocyclobutisoquinoline	15298-58-5	C9H5Cl2N	198.051

反应信息

• 作为反应物：
  描述：

  4-氯-1(2H-)-异喹啉酮 在 氯磺酸 、 sodium hydroxide 、 sodium hydride 、 potassium carbonate 、 三乙胺 、 三氯氧磷 作用下， 以 甲醇 、 二氯甲烷 、 二甲基亚砜 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 197.17h， 生成 Cycloleucine deriv. 38
  参考文献：
  名称：

  Selective Urokinase-Type Plasminogen Activator Inhibitors. 4. 1-(7-Sulfonamidoisoquinolinyl)guanidines

  摘要：

  1-isoquinolinylguanidines were previously disclosed as potent and selective inhibitors of urokinase-type plasminogen activator (uPA). Further investigation of this template has revealed that incorporation of a 7-sulfonamide group furnishes a new series of potent and highly selective uPA inhibitors. Potency and selectivity can be achieved with sulfonamides derived from a variety of amines and is further enhanced by the incorporation of sulfonamides derived from amino acids. The binding mode of these 1-isoquinolinylguanidines has been investigated by X-ray cocrystallization studies. uPA inhibitor 26 was selected for further evaluation based on its excellent enzyme potency (Ki 10 nM) and selectivity profile (4000-fold versus tPA and 2700-fold versus plasmin). In vitro, compound 26 is able to inhibit exogenous uPA in human chronic wound fluid (IC50=0.89 microM). In vivo, in a porcine acute excisional wound model, following topical delivery, compound 26 is able to penetrate into pig wounds and inhibit exogenous uPA activity with no adverse effect on wound healing parameters. On the basis of this profile, compound 26 (UK-371,804) was selected as a candidate for further preclinical evaluation for the treatment of chronic dermal ulcers.

  DOI：

  10.1021/jm061066t
• 作为产物：
  描述：

  3-chloro-3-phenyl-acryloyl azide 以 二苯基甲烷 为溶剂， 反应 4.0h， 以89%的产率得到4-氯-1(2H-)-异喹啉酮
  参考文献：
  名称：

  [EN] HEPATITIS C VIRUS INHIBITORS
  [FR] INHIBITEURS DU VIRUS DE L'HEPATITE C

  摘要：

  丙型肝炎病毒抑制剂的一般结构式（I）已被披露，其中A、R2、R3、R'、B和Y在描述中有所描述。还披露了包含这些化合物的组合物以及使用这些化合物抑制HCV的方法。

  公开号：

  WO2005051410A1

文献信息

• Novel Bicyclic Pyridinones
  申请人：Pettersson Martin Youngjin

  公开号：US20120252758A1

  公开（公告）日：2012-10-04

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  所述化合物及其药用可接受的盐被披露，其中所述化合物具有如本文所定义的Formula I的结构。相应的药物组合物、治疗方法、合成方法和中间体也被披露。
• Isoquinolines as urokinase inhibitors
  申请人：Pfizer Inc.

  公开号：US06248738B1

  公开（公告）日：2001-06-19

  Compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is H and the other is N═C(NH2)2 or NHC(═NH)NH2, and the other substituents are as defined herein, are urokinase (uPA) inhibitors.

  式(I)的化合物及其药用盐，其中R1和R2中的一个是H，另一个是NHC(NH2)2或NHC(NH)NH2，其他取代基如本文所定义，是尿激酶（uPA）抑制剂。
• Isoquinolines
  申请人：——

  公开号：US06093731A1

  公开（公告）日：2000-07-25

  Isoquinolinylguanidine compounds of formula (I): ##STR1## wherein the substituents are as defined herein, and salts thereof, are disclosed as urokinase inhibitors.

  公开了式(I)的异喹啉基胍化合物：##STR1##其中取代基如本文所定义，并公开了其盐，作为尿激酶抑制剂。
• Composition for the treatment of damaged tissue
  申请人：Pfizer Inc.

  公开号：US20030199440A1

  公开（公告）日：2003-10-23

  A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.

  描述了一种用于受损组织，如伤口治疗（例如愈合）的药物。该药物包括包含以下成分的组合物：（a）生长因子；和（b）抑制剂；以及可选的（c）药用载体、稀释剂或赋形剂；其中抑制剂可以抑制至少一种在受损组织，如伤口环境中上调的特定不良蛋白质（例如特定蛋白酶）的作用。
• PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20140206686A1

  公开（公告）日：2014-07-24

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了Formula (I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性的ROCK抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗心血管、平滑肌、肿瘤学、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。